Per favore
selezionare il paese

Attenzione, le pagine di questa sezione sono disponibili solo in lingua inglese.

Selezionando la visualizzazione internazionale, l'utente dichiara di risiedere al di fuori degli Stati Uniti e di voler visualizzare le informazioni sui prodotti internazionali di DiaSorin Molecular. Questo materiale è destinato esclusivamente ai visitatori internazionali (non statunitensi) del sito.

Ai sensi delle Linee Guida del Ministero della Salute del 28/03/2013 in materia di pubblicità sanitaria relativa a dispositivi medici, dispositivi medico-diagnostici in vitro e presidi medico-chirurgici, si informa che le informazioni contenute in questo sito e alle quali si accede sono destinate esclusivamente agli operatori professionali.

Simplexa™ C. auris Direct

CE-IVDR marked for the detection of Candida auris DNA

Pivotal aid in the prevention and control of a rapidly emerging multidrug-resistant fungal pathogen in healthcare settings.

Want to learn more?

Get updates

Disease state

Candida auris is an emerging multidrug-resistant fungal pathogen associated with severe nosocomial infections and is considered a serious global health threat.

The WHO and US Centers for Disease Control (CDC) have identified C. auris as a critical fungal pathogen causing outbreaks in more than 35 countries in the last decade and emerging as a significant healthcare concern associated with an urgent antimicrobial resistance threat.^1,2

C. auris is also associated with high mortality rates – one in three patients die within a month of being diagnosed with the infection.³ Like other potentially invasive fungal infections, immunocompromised patients are the most vulnerable to the dangers of C. auris infections.

Asymptomatic carriers must be identified to evaluate the risk of acute infection and potential spread in healthcare facilities.^3,4 Screening asymptomatic patients or those at risk for C. auris colonization is key to preventing the spread in healthcare facilities and is best conducted by testing swabs taken from the axilla and groin areas of hospitalized patients.⁵

1. Centers for Disease Control and Prevention, “Fact sheets” (2023). Available at: https://www.cdc.gov/fungal/candida- auris/fact-sheets/index.html

2. https://www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi

3. Tracking Candida auris | Candida auris | Fungal Diseases | CDC

4. Saris K., Meis J.F., Voss A. Candida auris. Curr. Opin. Infect. Dis. 2018;31:334–340.

5. www.cdc.gov/fungal/candida-auris/c-auris-screening

Candida auris is an emerging multidrug-resistant fungus that presents a serious global health threat

The value of Simplexa™ C. auris Direct

CE-IVDR marked for the detection of Candida auris DNA

Preventing outbreaks and protecting at-risk patients

Accurate and fast results help prevent C. auris hospital outbreaks and can protect fragile patients from potentially deadly outcomes.

Operational efficency with simple workflow

Less chance of error with sample-to-answer workflow without DNA extraction.

Excellent clinical performance

High performance in clinical trials: 94.8% sensitivity (PPA) and 98.7% specificity (NPA).

Clinically impactful

Timely and accurate identification of patients with suspected C. auris colonization supports infection control and prevention strategies in healthcare settings.

How the Simplexa™ C. auris Direct works

Simplexa™ C. auris Direct is a qualitative real-time PCR assay with a simple workflow for the in vitro qualitative detection of C. auris DNA from a composite swab of bilateral axilla/groin from patients suspected of C. auris colonization. Includes ready-to-use Simplexa™ C. auris Sample Prep Kit and PCR reagent for loading onto a reusable Direct Amplification Disc on the compact LIAISON^® MDX system. Designed for operational simplicity, flexibility, and quality assurance for utility across any clinical lab.

Sample-to-Answer

Scan 1-8 primary unextracted samples per run, ready-to-use single use reaction mix vials, and the 8-well Direct Amplification Disc. Simply load samples mixed in proprietary sample prep buffer and reagents directly onto the disc, place the disc on the LIAISON^® MDX system, and press run for results in less than 2 hours.

Intuitive LIAISON^® MDX Studio Software

Preinstalled with bidirectional connectivity allowing for simple run set-up, data analysis, and information management.

Broad clade coverage

Comprehensive coverage across all six global C. auris clades identified across the world.

Indications for Simplexa™ C. auris Direct use

Assay and system

A real-time PCR assay run on LIAISON^® MDX to detect C. auris DNA

Patient types

Human patients suspected of C. auris colonization in healthcare settings

Diagnostic lab

Hospital, Commercial, Reference, and Public Health laboratories

To be used on the LIAISON^® MDX System

The LIAISON^® MDX is an innovative and powerful real-time PCR instrument with two consumable disc options: the 8-well Direct Amplification Disc and the 96-well Universal Disc for higher volume testing.

Supported by an expanding menu of molecular assays, the system provides easy to understand results with the ability to check amplification curves after a run. All of this in a compact footprint measuring only 12″ by 8″ by 12″ so that it can fit into laboratories of any size.

LIAISON^® MDX

One instrument.
Multiple discs.
Ultimate Flexibility.

Discover more